Tarsus Pharmaceuticals, Inc. TARS Weighted Average Exercise Price of Vested and Expected to Vest Options
Weighted Average Exercise Price of Vested and Expected to Vest Options at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-K, filed February 23, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s weighted average exercise price of vested and expected to vest options.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s weighted average exercise price of vested and expected to vest options?
- Tarsus Pharmaceuticals, Inc. (TARS) reported weighted average exercise price of vested and expected to vest options of $17.76 in Q4 2025.
- How has Tarsus Pharmaceuticals, Inc.'s weighted average exercise price of vested and expected to vest options changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s weighted average exercise price of vested and expected to vest options increased by 10.0% year-over-year, from $16.15 to $17.76.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s weighted average exercise price of vested and expected to vest options?
- Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s weighted average exercise price of vested and expected to vest options has grown at a 60.3% compound annual growth rate (CAGR), from $1.68 to $17.76.
- What does weighted average exercise price of vested and expected to vest options mean?
- This is the weighted average price at which holders of vested and expected-to-vest stock options can purchase company shares. It provides a benchmark for the 'in-the-money' status of the company's equity incentive programs. Investors use this to assess the alignment between employee incentives and the current market price of the stock.